353 related articles for article (PubMed ID: 19373578)
1. Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody.
Zhang R; Qian J; Guo J; Yuan YF; Xue K
Curr Eye Res; 2009 Apr; 34(4):297-303. PubMed ID: 19373578
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
3. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
4. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
5. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
[TBL] [Abstract][Full Text] [Related]
7. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
8. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Kohno H; Sakai T; Saito S; Okano K; Kitahara K
Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
[TBL] [Abstract][Full Text] [Related]
9. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis.
Suzuki J; Sakai J; Okada AA; Takada E; Usui M; Mizuguchi J
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):314-21. PubMed ID: 11981647
[TBL] [Abstract][Full Text] [Related]
12. Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.
Martín AP; de Moraes LV; Tadokoro CE; Commodaro AG; Urrets-Zavalia E; Rabinovich GA; Urrets-Zavalia J; Rizzo LV; Serra HM
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2056-63. PubMed ID: 15914623
[TBL] [Abstract][Full Text] [Related]
13. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
14. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice.
Caspi RR; Chan CC; Grubbs BG; Silver PB; Wiggert B; Parsa CF; Bahmanyar S; Billiau A; Heremans H
J Immunol; 1994 Jan; 152(2):890-9. PubMed ID: 8283058
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of experimental autoimmune uveoretinitis induced by interphotoreceptor retinoid-binding protein.
Kawashima H; Fujiño Y; Mochizuki M
Jpn J Ophthalmol; 1991; 35(1):51-60. PubMed ID: 1895569
[TBL] [Abstract][Full Text] [Related]
16. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.
Zhang R; He R; Qian J; Guo J; Xue K; Yuan YF
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3575-82. PubMed ID: 20164461
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of experimental autoimmune uveoretinitis with anti-macrophage migration inhibitory factor antibodies.
Kitaichi N; Matsuda A; Kotake S; Namba K; Tagawa Y; Sasamoto Y; Ogasawara K; Iwabuchi K; Onoé K; Matsuda H; Nishihira J
Curr Eye Res; 2000 Feb; 20(2):109-14. PubMed ID: 10617911
[TBL] [Abstract][Full Text] [Related]
18. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis.
Xu H; Rizzo LV; Silver PB; Caspi RR
Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of intravitreal administration of tresperimus, an immunosuppressive drug, on experimental autoimmune uveoretinitis.
Bousquet E; Camelo S; Leroux les Jardins G; Goldenberg B; Naud MC; Besson-Lescure B; Lebreton L; Annat J; Behar-Cohen F; de Kozak Y
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5414-23. PubMed ID: 21666239
[TBL] [Abstract][Full Text] [Related]
20. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12.
Yokoi H; Kato K; Kezuka T; Sakai J; Usui M; Yagita H; Okumura K
Eur J Immunol; 1997 Mar; 27(3):641-6. PubMed ID: 9079803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
